WHO Drug Information Vol. 19, No. 3, 2005
(2005; 72 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoPersonal Perspectives
Cerrar esta carpetaSafety and Efficacy Issues
Ver el documentoTransdermal fentanyl: abuse by adolescents
Ver el documentoSafety of fentanyl transdermal patches
Ver el documentoRosiglitazone: decreased high-density lipoprotein cholesterol
Ver el documentoIbuprofen: Stevens-Johnson syndrome
Ver el documentoStringent conditions for COX-2 Inhibitors
Ver el documentoSildenafil, tadalafil and vardenafil: eye problems reported
Ver el documentoNesiritide: safety report and measures
Ver el documentoMifepristone, sepsis and blood infection
Ver el documentoMifepristone: revised safety information
Ver el documentoSuicidality with SSRIs in adults
Ver el documentoEzetimibe and muscle disorders
Ver el documentoPathological gambling with cabergoline
Ver el documentoIcodextrin peritoneal dialysis solution: falsely elevated blood glucose readings
Ver el documentoNew requirements for pseudoephedrine products
Ver el documentoEfalizumab: warning of thrombocytopenia
Ver el documentoAntiretrovirals: HIV, hepatic impairment and HBV/HCV
Abrir esta carpeta y ver su contenidoHerbal Medicines
Abrir esta carpeta y ver su contenidoRegulatory Action and News
Abrir esta carpeta y ver su contenidoEssential Medicines
Abrir esta carpeta y ver su contenidoAccess to Medicines
Abrir esta carpeta y ver su contenidoThe International Pharmacopoeia
Ver el documentoRecommended International Nonproprietary Names: List 54

Ezetimibe and muscle disorders

Australia - Ezetimibe (Ezetrol®) lowers lipids by inhibiting the intestinal absorption of cholesterol and is indicated for the treatment of hypercholesterolaemia. Out of 144 Australian reports received with ezetimibe since registration in June 2003, 44 have been of muscle disorders, including myalgia, muscle cramp, weakness and pain with five reports describing increased serum creatine kinase and three listing symptoms possibly indicative of an allergic reaction.

In premarketing clinical trials, reported rates of myalgia were less than 2% with ezetimibe, 2.4% with statins and 3.2% with ezetimibe coadministered with a statin (1). The association of the lipid-lowering statins (atorvastatin, fluvastatin, pravastatin, simvastatin) with muscle disorders, including rhabdomyolysis, is well-known (2). Although ezetimibe has been associated with muscle disorders, at present it is uncertain whether it can cause rhabdomyolysis, and if so what factors increase the risk (3).

In the 44 cases reported to the Australian Adverse Reactions Advisory Committee (ADRAC) with muscle disorders, the time to onset ranged from hours to approximately 4 months, but in almost half of the cases, the symptoms developed within two weeks. Twenty-one patients had a history of muscle disorder or increased creatine kinase with statins.

Ezetimibe was given concomitantly with a statin in 5 of the 44 cases and in two published cases (4). The details of these cases are consistent with an interaction between the statin and ezetimibe. Typically, the patient had been taking the statin long term, and the symptoms of myalgia or increase in creatine kinase developed within three months of the addition of ezetimibe. Four patients recovered on withdrawal of ezetimibe alone, and another tolerated reintroduction of atorvastatin 80 mg daily without ezetimibe.

Extracted from the Australian Adverse Drug Reactions Bulletin, Volume 24, Number 4, August 2005


1. Ezetrol, Australian Product Information, Merck Sharp & Dohme (Aust.) Pty Ltd. 2 Jun 2004.

2. ADRAC. Risk factors for myopathy and rhabdomyolysis with the statins. Aust Adv Drug Reactions Bull 2004;23:2.

3. Association of Ezetrol (ezetimibe) with myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia. Public Advisory Health Canada and Merck Frosst/Schering Pharmaceuticals, 1 Feb 2005. Internet: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ezetrol_hpc_e.html

4. Fux R, Mörike K, Gundel U-F, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004;140:671-2.

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018